People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Imbria Pharmaceuticals, Inc. | — | Biotechnology | Series C | $140.2M | $405.5M | 2025 |
| Pahr Therapeutics, Inc. | — | Biotechnology | Series A | $4.7M | $17.8M | 2025 |
Ken Horne at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ken Horne on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 2 | 17 |
| Zina Affas Besse | 1 | 4 |
| Rebecca Luse | 1 | 3 |
| Neil Buckley | 1 | 3 |
| Atsushi Usami | 1 | 3 |
| Charles Dunn | 1 | 2 |
| Komal Joshi | 1 | 1 |
| Pavan Cheruvu | 1 | 1 |
| James Januzzi | 1 | 1 |
| Andrew C. Levin | 1 | 1 |
| David-Alexandre C. Gros | 1 | 1 |
| James C. Januzzi | 1 | 1 |
| Pieter C. Boelhouwer | 1 | 1 |
| Amanda Creedon | 1 | 1 |
| Luse Rebecca | 1 | 1 |
| Alvin Shih | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.